Concepedia

Author

Yuko Akiyama

Saitama Medical UniversityORCID

Also Known As

Y. Akiyama, Yo Akiyama, Yuko AKIYAMA, Yuko Akiyama

40

Publications

1.3K

Citations

16

H-Index

51

Concepts

All Affiliations

Saitama Medical UniversityNihon UniversitySurugadai Nihon University HospitalSaitama International Medical CenterNational Defense Medical College
YA

About

Yuko Akiyama is an author at Saitama Medical University specializing in medicine, cell biology, and cellular physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

838

2

Health Sciences

2

2

51

3

Biochemistry

2

2

51

4

Engineering

1

1

16

5

Anatomy

1

1

16

Yuko Akiyama

×

20

Publications

1.3K

Citations

16

H-Index

YearCitations

Lipocalin-2 Resistance Confers an Advantage to Salmonella enterica Serotype Typhimurium for Growth and Survival in the Inflamed Intestine

Manuela Raffatellu, Michael D. George, Yuko Akiyama,

Cell Host & Microbe

2009

514

Removal of hazardous phenols by microalgae under photoautotrophic conditions

Takashi Hirooka, Yuko Akiyama, Naoki Tsuji,

Journal of Bioscience and Bioengineering

2003

119

Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer

Ken‐ichi Fujita, Wataru Yamamoto, Toshimichi Miya,

Cancer Chemotherapy and Pharmacology

2009

102

<i>CYP2A6</i>and the plasma level of 5‐chloro‐2, 4‐dihydroxypyridine are determinants of the pharmacokinetic variability of tegafur and 5‐fluorouracil, respectively, in Japanese patients with cancer given S‐1

Ken‐ichi Fujita, Wataru Yamamoto, Shoji Endo,

Cancer Science

2008

62

Periodontal tissue regeneration by transplantation of rat adipose-derivedstromal cells in combination with PLGA-based solid scaffolds

Daisuke Akita, Masakazu Morokuma, Yōko Saitō,

Biomedical Research

2014

61

Sorafenib and Sunitinib, Two Anticancer Drugs, Inhibit CYP3A4-Mediated and Activate CY3A5-Mediated Midazolam 1′-Hydroxylation

Minako Sugiyama, Ken‐ichi Fujita, Norie Murayama,

Drug Metabolism and Disposition

2011

51

The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1

Ken‐ichi Fujita, Minako Sugiyama, Yuko Akiyama,

Cancer Chemotherapy and Pharmacology

2010

48

Alkaline phosphatase determines polyphosphate-induced mineralization in a cell-type independent manner

Yoshikazu Mikami, Hiromasa Tsuda, Yuko Akiyama,

Journal of Bone and Mineral Metabolism

2015

38

Association of ATP-Binding Cassette, Sub-family C, Number 2 (ABCC2) Genotype with Pharmacokinetics of Irinotecan in Japanese Patients with Metastatic Colorectal Cancer Treated with Irinotecan Plus Infusional 5-Fluorouracil/Leucovorin (FOLFIRI)

Ken‐ichi Fujita, Fumio Nagashima, Wataru Yamamoto,

Biological and Pharmaceutical Bulletin

2008

38

UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer

Yu Sunakawa, Wataru Ichikawa, Ken‐ichi Fujita,

Cancer Chemotherapy and Pharmacology

2010

38

Page 1